5e70ba2109b32d0004a916bd_1.jpg
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
July 28, 2022 07:30 ET | Todos Medical Ltd.
NEW YORK, NY, AND TEL AVIV, ISRAEL, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today...
5e70ba2109b32d0004a916bd_1.jpg
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
June 23, 2022 07:00 ET | Todos Medical Ltd.
83% of Respondents With Acute COVID Were Satisfied 68% of Respondents With Long COVID Were Satisfied NEW YORK, NY, and TEL AVIV, ISRAEL, June 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –...
5e70ba2109b32d0004a916bd_1.jpg
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
November 18, 2021 06:00 ET | Todos Medical Ltd.
The Agreement Calls for a Minimum of 500,000 Bottles in Sales Over 18 Months T-Cell Protect to Invest 1 Million Euros in Todos to Support Development of Tollovir, the Company’s 3CL Protease...